Drug intelligence / Profile preview

MVA-NYESO

Development stage: Phase 2
Lead developer: Barinthus Biotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

MVA-NYESO is a vaccine component using the Modified Vaccinia Ankara (MVA) viral vector to deliver the NY-ESO-1 antigen. It is part of a prime-boost immunotherapy strategy, aiming to stimulate the immune system against cancer cells expressing NY-ESO-1. The MVA vector is a severely weakened form of the poxvirus, incapable of causing disease, and is used as a booster in immunotherapy regimens.

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)

Beyond the preview

Go deeper on MVA-NYESO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-NYESO.

Explore the full profile